What is the risk of pneumonia associated with adalimumab in a patient with COPD, rheumatoid arthritis, moderate emphysema, and asthma?
No direct evidence for the specific risk of pneumonia associated with adalimumab in a patient with COPD, RA, moderate emphysema, and asthma was identified. However, there is an elevated general risk of serious infections, including pneumonia, with adalimumab treatment, particularly when used alongside other immunosuppressants.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-10-26
- DOI
- https://doi.org/10.5281/zenodo.23666107
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00